TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SAMSN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-length & Domain Truncation) | SAMSN1 Recombinant Protein (Full-length & SH3-only/SAM-only domains). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 expressed. Theoretical MW confirmed. | View SAMSN1 Products |
| Gene Delivery | SAMSN1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line generation. CMV promoter, Puromycin selection. | View SAMSN1 Products |
| Benchmark/Research Antibody | Anti-SAMSN1 Recombinant Antibody (Monoclonal). High-affinity positive control for WB/IHC/Flow Cytometry. | View SAMSN1 Products |
| Functional Validator | SAMSN1 siRNA Set (3 unique duplexes). Sequence-verified for reliable knockdown verification. | View SAMSN1 Products |
| Domain Mapping Set | SAMSN1 Domain Truncation Panel (SH3-only / SAM-only). Individual domains for binding site mapping. | View SAMSN1 Products |
| Paralog Control | SAMSN2 Recombinant Protein. Closest paralog for specificity screening. High Purity (>95%), Sequence Verified. | View SAMSN2 Products |
| Related Target: BTK | Bruton's Tyrosine Kinase. Synergistic B-cell receptor signaling pathway node. | View BTK Products |
| Related Target: PIK3CA | Downstream oncogenic survival pathway mediator. | View PIK3CA Products |
| Related Target: SASH1 | SAM-domain family member; essential selectivity counter-screening for SAMSN1-targeted ligands. | View SASH1 Products |
| Related Target: CSF1R | Macrophage polarization axis; tumor-associated macrophage modulation. | View CSF1R Products |
| Related Target: BLNK | B-Cell Linker Protein; known SAMSN1 interacting partner in BCR signaling. | View BLNK Products |
Critical Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PROTAC/Small Molecule Binding Validation | High-purity recombinant proteins with intact SAM and SH3 domains, validated by Theoretical MW and strict structural QC. |
| Intracellular Degradation Monitoring | Pre-packaged Lentivirus for generating stable SAMSN1-overexpressing cell lines, enabling robust cellular assays. |
| Lack of Reliable Assay Controls | Recombinant positive control antibodies strictly sequence-verified for reproducible lot-to-lot performance. |
| Target Specificity (False Positives) | Endotoxin-controlled siRNA sets included for precise target specificity and functional knockdown checks. |
| Domain-Specific PPI Mapping (SH3 vs SAM) | Strict domain boundary truncations verified by Mass Spec; soluble expression in HEK293. |
| Paralog Selectivity (SAMSN1 vs SAMSN2) | Ortholog panel with sequence-verified distinction at binding interfaces. |
| Cross-species Translation (Human/Mouse/Cyno) | Ortholog proteins available; Sequence Verified by LC-MS/MS. |
| Off-target Liability within SAM-domain Family | Homolog panel (SASH1, SAMD9, SAMD9L) strictly verified by mass spec for selectivity assays. |
Live SAMSN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
- ➤ DLBCL & Lymphoma Research
- ➤ Autoimmune Disease Mechanisms
Global Clinical Landscape & Future Outlook
SAMSN1 (also known as HACS1 or NASH1) is an intracellular adaptor protein with SH3 and SAM domains, primarily expressed in hematopoietic cells. It acts as a negative regulator of B-cell receptor signaling and is implicated in multiple myeloma, gastric cancer, glioblastoma, diffuse large B-cell lymphoma (DLBCL), and autoimmune pathologies. Traditionally considered undruggable due to lack of enzymatic active sites, SAMSN1 has become a focal point for targeted protein degradation (PROTACs), RNA interference (RNAi), and protein-protein interaction (PPI) inhibitors. The current R&D landscape is dominated by academic consortia and specialized biotechs exploring domain-specific disruption strategies. As first-generation screening campaigns advance, the next wave of R&D is expected to focus on cell-permeant ligand discovery, PROTAC optimization, and combination approaches with B-cell receptor pathway inhibitors (e.g., BTK inhibitors) and immune checkpoint inhibitors. The field also anticipates the development of selective SAMSN1-SASH1 axis modulation and validation of SAMSN1 as a biomarker for patient stratification.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Molecular Glues | Early-stage Biotechs, Academic Spin-offs | Multiple Myeloma, Solid Tumors | Direct Binding Assays (SPR/BLI) requiring high-purity domain-specific recombinant proteins. Cell-based degradation assays require stable overexpression lentivirus. |
| RNAi / ASOs | Gene Therapy Innovators, Immunology-focused Biotechs | Autoimmune Diseases, Lymphoma, Functional Genomics | In vitro knockdown validation using sequence-verified siRNA and Lentivirus cell lines. |
| Small Molecule PPI Inhibitors | Preclinical Oncology Pharma, Academic Consortia | Gastric Cancer, Glioblastoma, DLBCL | Domain-specific binding assays (SAM-only and SH3-only proteins >95% pure). Protein-protein interaction screening. |
| Peptide Mimetics | Peptide Therapeutics Focus | Autoimmune Diseases (SLE, RA) | Conformational stability screening requiring full-length native protein. |
| Biologic (ADC potential) | Exploratory Programs | Hematologic Malignancies | Internalization & expression validation using Lentivirus for cell line engineering. |
| Gene Silencing (siRNA/ASO) | Functional Genomics Research | Various | Knockdown efficiency & specificity validation with validated siRNA + qPCR controls. |